Tang Capital Management GRAL Position
Exited5-Fund ConvergenceTang Capital Management exited their position in GRAIL, Inc. (GRAL) in Q2 2025, after holding the stock for 3 quarters.
The position was first reported in Q4 2024 and has been tracked across 3 quarterly 13F filings.
GRAL is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 18.0% of float with 2.9 days to cover, indicating significant bearish positioning against the stock.
About GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Full company profile →Short Interest
18.0%
2.9 days to cover
Tang Capital Management GRAL Position History
Frequently Asked Questions
Does Tang Capital Management own GRAL?
No. Tang Capital Management exited their position in GRAIL, Inc. (GRAL) in Q2 2025. They previously held the stock for 3 quarters.
How many hedge funds own GRAL?
5 specialist biotech hedge funds currently hold GRAL, including Baker Bros. Advisors, Deep Track Capital, RA Capital Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy GRAL?
Tang Capital Management's position in GRAL was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's GRAL position increasing or decreasing?
Tang Capital Management completely exited their GRAL position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GRALCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →